

TRIAL STATISTICAL ANALYSIS PLAN

Document No.:	228892_377986_1.0
BI Trial No.:	1447-0010
Title:	A double-micro-tracer human absorption, distribution, metabolism and excretion (hADME) and absolute bioavailability trial after a single oral dose of BI 1569912 (C-14) and a single, concomitant, intravenous micro-dose of BI 1569912 (C-13) in healthy male subjects (a phase I, open-label, non-randomised, single-dose, fixed-sequence trial) (including Protocol Amendment No.1-2 [228892_1076999_3.0])
Investigational Product:	BI 1569912
Responsible trial statistician:	<div></div> Phone: + <div></div> Fax: + <div></div>
Date of statistical analysis plan:	10 DEC 2024
Version:	1.0
Page 1 of 30	
<p align="center">Proprietary confidential information</p> <p>© 2024 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved. This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permission.</p>	

1. TABLE OF CONTENTS

TITLE PAGE.....	1
1. TABLE OF CONTENTS	2
LIST OF TABLES	4
2. LIST OF ABBREVIATIONS.....	5
3. INTRODUCTION	7
4. CHANGES IN THE PLANNED ANALYSIS OF THE STUDY	8
5. ENDPOINTS.....	9
5.1 PRIMARY ENDPOINTS	9
5.2 SECONDARY ENDPOINTS	9
5.2.1 Key secondary endpoints	9
5.2.2 Secondary endpoints	9
6. GENERAL ANALYSIS DEFINITIONS.....	12
6.1 TREATMENTS.....	12
6.2 IMPORTANT PROTOCOL DEVIATIONS	13
6.3 INTERCURRENT EVENTS.....	13
6.4 SUBJECT SETS ANALYSED	14
6.6 HANDLING OF MISSING DATA AND OUTLIERS	15
6.7 BASELINE, TIME WINDOWS AND CALCULATED VISITS.....	16
7. PLANNED ANALYSIS	17
7.1 DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS	18
7.2 CONCOMITANT DISEASES AND MEDICATION.....	18
7.3 TREATMENT COMPLIANCE	19
7.4 PRIMARY OBJECTIVE ANALYSIS	19
7.4.1 Main analysis	19
7.5 SECONDARY OBJECTIVE ANALYSIS	21
7.5.1 Key secondary objective analysis.....	21
7.5.2 Secondary objective analysis	21
7.7 EXTENT OF EXPOSURE	21
7.8 SAFETY ANALYSIS	21
7.8.1 Adverse Events	21
7.8.2 Laboratory data.....	23
7.8.3 Vital signs	23
7.8.4 ECG	24

8.	TIMEPOINT OF RELEASE OF TREATMENT INFORMATION	26
9.	REFERENCES	27
11.	HISTORY TABLE	30

LIST OF TABLES

Table 6.1: 1 Treatments and labels used in the analysis12
Table 6.4: 1 Subject sets analysed15
Table 11: 1 History table30

2. LIST OF ABBREVIATIONS

See Medicine Glossary:

<http://glossary>

Term	Definition / description
ALT	Alanine Aminotransferase
ANOVA	Analysis of variance
AST	Aspartate Aminotransferase
AUC _{0-∞}	Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity in plasma
AUC _{0-tz}	Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point in plasma
BMI	Body mass index
CDR	Clinical Data Repository
CI	Confidence interval
C _{max}	Maximum measured concentration of the analyte in plasma
C-SSRS	Columbia Suicide Severity Rating Scale
CTP	Clinical trial protocol
CTR	Clinical trial report
CV	Arithmetic Coefficient of Variation
DILI	Drug induced liver injury
eDMS	Electronic documentation management system
fe _{faeces,0-tz}	Fraction excreted in faeces as percentage of the administered dose over the time interval from 0 to the last quantifiable time point
fe _{urine,0-tz}	Fraction excreted in urine as percentage of the administered dose over the time interval from 0 to the last quantifiable time point
gCV	Geometric Coefficient of Variation
gMean	Geometric Mean
hADME	Human ADME
i.v.	intravenous
INR	International Normalization Ratio
Max	Maximum
Min	Minimum

Term	Definition / description
N	Number non-missing observations
Nobs	Number of observations
os	oral solution
P10	10 th percentile
P90	90 th percentile
PK	Pharmacokinetic
PKS	PK parameter analysis set
Q1	1 st quartile
Q3	3 rd quartile
R	Reference treatment
RAGe	Report Appendix Generator system
RPM	Report Planning Meeting
SD	Standard Deviation
T	Test treatment
t _{max}	Time from (last) dosing to the maximum measured concentration of the analyte in plasma
TS	Treated set
TSAP	Trial Statistical Analysis Plan
ULN	Upper Limit of Normal

3. INTRODUCTION

As per ICH E9 (1), the purpose of this document is to provide a more technical and detailed elaboration of the principal features of the analysis described in the protocol, and to include detailed procedures for executing the statistical analysis of the primary and secondary variables and other data.

This TSAP assumes familiarity with the CTP, including Protocol Amendments. In particular, the TSAP is based on the planned analysis specification as written in CTP Section 7 “Statistical Methods and Determination of Sample Size”. Therefore, TSAP readers may consult the CTP for more background information on the study, e.g., on study objectives, study design and population, treatments, definition of measurements and variables, planning of sample size.

Study data (including data entered in the RAVE EDC system and external data provided by suppliers) will be stored in a CDR.

PK parameters will be calculated using Phoenix WinNonlinTM software (version 8.1.1 or higher, [REDACTED]) or SAS Version 9.4 (or later version).

The statistical analyses will be performed within the validated working environment CARE, including SASTM (current Version 9.4, by [REDACTED]), and a number of SASTM-based tools (e.g., macros for the analyses of AE data or laboratory data; RAGe for compilation/formatting of the CTR appendices).

4. CHANGES IN THE PLANNED ANALYSIS OF THE STUDY

All analyses as planned in the CTP will be performed and are described in more detail in this TSAP.

5. ENDPOINTS

5.1 PRIMARY ENDPOINTS

Section 2.1.2 of the CTP:

hADME endpoints for [^{14}C]- radioactivity in urine and faeces:

Mass balance recovery for [^{14}C]- radioactivity in urine and faeces after oral administration of BI 1569912 (C-14):

- *$fe_{urine,0-tz}$ (fraction excreted in urine as percentage of the administered dose over the time interval from 0 to the last quantifiable time point).*
- *$fe_{faeces,0-tz}$ (fraction excreted in faeces as percentage of the administered dose over the time interval from 0 to the last quantifiable time point).*
- *Sum of $fe_{urine,0-tz}$ and $fe_{faeces,0-tz}$ (total recovery of [^{14}C]-radioactivity).*

Absolute BA endpoints for BI 1569912 and [^{13}C] BI 1569912 in plasma:

The following pharmacokinetic parameters will be determined for BI 1569912 and [^{13}C] BI 1569912 in plasma:

- *$AUC_{0-\infty}$ (area under the concentration-time curve of the analyte over the time interval from 0 extrapolated to infinity in plasma) of BI 1569912 after a single oral administration of BI 1569912 (C-14).*
- *$AUC_{0-\infty}$ (area under the concentration-time curve of the analyte over the time interval from 0 extrapolated to infinity in plasma) of [^{13}C] BI 1569912 after a single intravenous infusion of BI 1569912 (C-13).*

5.2 SECONDARY ENDPOINTS

5.2.1 Key secondary endpoints

This section is not applicable as no key secondary endpoints have been defined in the CTP.

5.2.2 Secondary endpoints

Section 2.1.3 of the CTP:

hADME and Absolute BA endpoints for BI 1569912 in plasma:


- *C_{max} (maximum measured concentration of the analyte in plasma) of BI 1569912 after a single oral administration of BI 1569912 (C-14).*
- *AUC_{0-tz} (area under the concentration-time curve of the analyte over the time interval from 0 to the last quantifiable time point in plasma) of BI 1569912 after a single oral administration of BI 1569912 (C-14).*

hADME endpoints for [^{14}C]-radioactivity in plasma:

- C_{\max} (maximum measured concentration of the analyte in plasma) of [^{14}C]-radioactivity after a single oral administration of BI 1569912 (C-14).
- AUC_{0-t_z} (area under the concentration-time curve of the analyte over the time interval from 0 to the last quantifiable time point in plasma) of [^{14}C]-radioactivity after a single oral administration of BI 1569912 (C-14).

Absolute BA endpoints for [^{13}C] BI 1569912:

- C_{\max} of [^{13}C] BI 1569912 after a single intravenous administration of BI 1569912 (C-13).
- AUC_{0-t_z} of [^{13}C] BI 1569912 after a single intravenous administration of BI 1569912 (C-13).



6. GENERAL ANALYSIS DEFINITIONS

6.1 TREATMENTS

For basic study information on treatments to be administered, assignment of treatment groups, selection of doses, refer to CTP Sections 3 and 4.

The trial is designed as an open-label, non-randomised, single-dose, fixed sequence trial in healthy male subjects in order to investigate the basic pharmacokinetics of BI 1569912 and [¹⁴C]- radioactivity, including mass balance, excretion pathways, and metabolism following a single oral dose of [REDACTED] BI 1569912 (C-14) [test treatment, T], and the absolute bioavailability of BI 1569912 and [¹³C]- radioactivity after a single, concomitant intravenous micro-tracer administration of a single dose of [REDACTED] BI 1569912 (C-13) [reference treatment, R]. A total of 8 healthy male subjects are planned to participate in the trial.

For details of dosage and formulation see Table 6.1: 1 below.

Table 6.1: 1 Treatments and labels used in the analysis

Treatment (based on database)		Short label
TR	BI 1569912, solution (C-14), oral, [REDACTED], qd / BI 1569912, solution (C-13), i.v., [REDACTED] (10 mL), qd	BI 1569912 (C-14) os - BI 1569912 (C-13) iv

For PK analysis, test and reference formulations have to be distinguished. The following labels will be used (Section 9.5 and Appendix 10.5.3):

BI 1569912 (C-13) iv (R)

BI 1569912 (C-14) os (T)

Section 1.2.7 of the CTP:

The Residual Effect Period (REP) of BI 1569912 in humans is not known to date. This is the period after the last dose with measurable drug levels and/ or pharmacodynamic effects still likely to be present. Based on the pharmacokinetic half-life of about 4 h, it could be determined with about [REDACTED] until further information is available.

Based on this, the following study phases will be defined for the analysis of adverse events (AEs):

- **Screening**
 - Ranging from 0:00 h on day of informed consent until time of first drug administration (i.e. BI 1569912 (C-14)).
- **On-treatment** (labelled with short label)

“BI 1569912 (C-14) os - BI 1569912 (C-13) iv ”:

- Ranging from drug administration of BI 1569912 (C-14) until [REDACTED] after end of drug administration of BI 1569912 (C-13) or until trial termination (0:00 h on the day after trial termination), whatever occurs first.
- **Follow-up** (labelled “F/U”)
 - Ranging from the end of REP, which is defined as [REDACTED] until trial termination (0:00 h on the day after trial termination).

Note that AEs occurring after the last per protocol contact but entered before data base lock of the trial will be reported to Pharmacovigilance only and will not be captured in the trial database.

The following AE displays will be provided in the report:

In Section 9.3 and Appendix 10.5.1.8 (for ClinicalTrials.gov and EudraCT only) of the CTR displays, the on-treatment phase will be analysed (labelled with the short label of the study treatment as in [Table 6.1: 1](#), the actual treatment is equal to the study treatment). The screening and follow-up phases will not be included in this analysis.

In Section 9.4 and Appendix 10.6 (Listings) of the CTR displays, the screening period, as well as the follow-up phases will additionally be included and no totals will be provided.

For detailed information on the handling of the treatments refer to Technical TSAP ADS (analysis data set) plan and Analysis Data Reviewers guide.

6.2 IMPORTANT PROTOCOL DEVIATIONS

Data discrepancies and deviations from the CTP will be identified for all treated subjects. Consistency check listings (for identification of deviations of time windows) and a list of protocol deviations (e.g. deviations in drug administration, in blood sampling times, etc.) will be provided to be discussed at the Report Planning Meeting (RPM). At this meeting, all manual deviations identified at the sites by the CRAs and deviations too complex to program will be reviewed by the trial team to decide which are considered important. For definition of important protocol deviations (iPD), and for the process of identification of these, refer to the Boehringer Ingelheim (BI) SOP “Identify and Manage Important Protocol Deviations (iPD)” [\(2\)](#).

iPD categories will be suggested in the DV domain sheet, iPDs will be identified no later than in the RPM, and the iPD categories will be updated as needed.

If any iPDs are identified, they are to be summarised into categories and will be captured in the iPD specification file (DV domain) [\(3\)](#) and in the decision log [\(4\)](#). Both documents will be stored within the TMF in eDMS.

The iPDs will be summarized and listed in the CTR.

6.3 INTERCURRENT EVENTS

This section is not applicable.

6.4 SUBJECT SETS ANALYSED

Section 7.2.1.1 of the CTP:

Statistical analyses will be based on the following analysis sets:

- *Treated set (TS): The treated set includes all subjects who were treated with at least one dose of trial drug. The treated set will be used for safety analyses.*
- *Pharmacokinetic parameter analysis set (PKS): This set includes all subjects in the treated set (TS) who provide at least one PK endpoint that was defined as primary or secondary and was not excluded due to a protocol deviation relevant to the evaluation of PK or due to PK non-evaluability (as specified [...] below). Thus, a subject will be included in the PKS, even if he/she contributes only one PK parameter value for one period to the statistical assessment. Descriptive and model-based analyses of PK parameters will be based on the PKS.*

Section 7.2.1.2 of the CTP:

The pharmacokinetic parameters listed in CTP Section 2.1 and 2.2.2 for BI 1569912 will be calculated according to the relevant BI internal procedures.

Whole blood, plasma, urine, and faeces concentration data and parameters of a subject will be included in the statistical PK analyses if they are not flagged for exclusion due to a protocol deviation relevant to the evaluation of PK (to be decided no later than in the RPM) or due to PK non-evaluability (as revealed during data analysis, based on the criteria specified below). Exclusion of a subject's data will be documented in the CTR.

Important protocol deviations may be

- *Incorrect trial medication taken, i.e. the subject received at least one dose of trial medication the subject was not assigned to*
- *Incorrect dose of trial medication taken*
- *Use of restricted medications*

Whole blood, plasma, urine, and faeces concentrations and/or parameters of a subject will be considered as non-evaluable, if for example

- *The subject experienced emesis that occurred at or before two times median t_{max} of the respective treatment (Median t_{max} is to be determined excluding the subjects experiencing emesis)*
- *A predose concentration is $>5\%$ C_{max} value of that subject*
- *Missing samples/concentration data at important phases of PK disposition curve*

Whole blood, plasma, urine, and faeces concentration data and parameters of a subject which are flagged for exclusion will be reported with its individual values but will not be included in the statistical analyses. Descriptive and inferential statistics of PK parameters will be based on the PKS.

Only concentration values within the validated concentration range and actual sampling times will be used for the calculation of PK parameters. Concentrations used in the

pharmacokinetic calculations will be in the same format provided in the bioanalytical report, (that is, to the same number of decimal places provided in the bioanalytical report).

Table 6.4: 1 Subject sets analysed

Class of endpoint	Subject analysis set	
	TS	PKS
Analyses of primary, secondary or further PK endpoints		X
Safety assessments	X	
Disposition	X	
Demographic/baseline parameters	X	
Important protocol deviations	X	
Exposure	X	

6.6 HANDLING OF MISSING DATA AND OUTLIERS

Handling of missing data and outliers will be performed as described in the CTP, Section 7.3.

Missing or incomplete AE dates are imputed according to BI standards (see BI-KMED-BDS-HTG-0035) (5).

Missing data and outliers of PK data are handled according to BI standards (see “Standards and processes for analyses performed within Clinical Pharmacokinetics/Pharmacodynamics” (6) and “Noncompartmental Pharmacokinetic / Pharmacodynamic Analyses of Clinical Studies” (7)).

PK parameters that cannot be reasonably calculated based on the available drug concentration-time data will not be imputed.

6.7 BASELINE, TIME WINDOWS AND CALCULATED VISITS

The baseline value is defined as the last measurement before (first) drug administration.

Section 6.1 of the CTP:

If not stated otherwise in the CTP Flow Chart, the acceptable deviation from the scheduled time for vital signs, ECG, and laboratory tests will be ± 30 min.

Adherence to time windows will be checked via the consistency check listings at the RPM.

Unscheduled measurements of laboratory data and vital signs data will be assumed to be repeat measurements of the most recent scheduled measurement (e.g. for follow-up or confirmation of a particular value). Therefore, unscheduled measurements will be assigned to the planned time point of the previous scheduled measurement.

7. PLANNED ANALYSIS

Safety analysis (refer to [Section 7.8](#)) will be performed by [REDACTED] and will be presented in Sections 9.1 to 9.4 of the CTR and in Appendix 10.5.1 and 10.6.

Inferential statistical analyses of PK endpoints (refer to [Section 7.4](#) and [Section 7.5.2](#)) will also be performed by [REDACTED] and will be presented in Section 9.5 of the CTR and in Appendix 10.5.3.

Descriptive data analysis of PK endpoints and concentrations will be performed by the [REDACTED] and will be presented in Section 9.6 of the CTR and in Appendix 10.5.5.

The format of the listings and tables will follow the BI standards (see “Standards for Reporting of Clinical Trials and Project Summaries” ([8](#))) with the exception of those generated for PK-calculations following BI standards for PK/PD analysis (see “Graphs and Tables for Clinical Pharmacokinetics and Pharmacodynamic Noncompartmental Analyses” ([9](#))).

The individual values of all subjects will be listed, sorted by treatment group, subject number, visit and time point. The listings will be included in Appendix 10.6 of the CTR.

For end-of-text tables, the set of summary statistics for non-PK parameters is:

N	number non-missing observations
Mean	arithmetic mean
SD	standard deviation
Min	minimum
Median	median
Max	maximum

For analyte concentrations and PK parameters, the following descriptive statistics will additionally be calculated:

Nobs	number of observations
CV	arithmetic coefficient of variation
gMean	geometric mean
gCV	geometric coefficient of variation
P10	10th percentile
Q1	1st quartile
Q3	3rd quartile
P90	90th percentile

The data format for descriptive statistics of concentrations will be identical to the data format of the respective concentrations. The descriptive statistics of PK parameters will be calculated using the individual values with the number of decimal places as provided by the evaluation program. Then the individual values as well as the descriptive statistics will be reported with three significant digits in the CTR.

The gMeans and gMean ratio based on the inferential statistics will be reported with maximum of 2 decimal places.

Tabulations of frequencies for categorical data will include all possible categories available in the CRF and will display the number of observations in a category, as well as the percentage (%). The precision for percentages should be one decimal point, unless the denominator is smaller than 100 (in all treatment columns), in which case percentages are given in integer numbers. The category 'missing' will be displayed only if there are actually missing values.

Units of variables should be given in the titles or column/row descriptors in brackets (e.g. (mg)).

Exclusion of PK parameters

The ADS “ADPP” (PK parameters) contains column variables APEX and APEXCO indicating inclusion/exclusion (APEX) of a PK parameter and an analysis flag comment (APEXCO). All analyses based on the PKS will include parameters only if they are not flagged for exclusion, that is APEX is equal to “Included”.

Exclusion of PK concentrations

The ADS “ADPC” (PK concentrations per time-point or per time-interval) contains column variables ACEX and ACEXCO indicating inclusion/exclusion (ACEX) of a concentration and an analysis flag comment (ACEXCO). Exclusion of a concentration depends on the analysis flag comment ACEXCO. For example, if ACEXCO is set to ‘ALL CALC’, the value will be excluded for all types of analyses based on concentrations. If ACEXCO is set to ‘DESC STATS’ the value will be excluded from descriptive evaluations per planned time point/time interval. If ACEXCO contains the addition ‘TIME VIOLATION’ or ‘TIME DEVIATION’ the value can be used for further analyses based on actual times. If ACEXCO is set to ‘HALF LIFE’, the value will be excluded from half-life calculation (and, as a consequence, any calculation that relies on λ_z) only; the value is included for all other analyses.

Further details are given in “Noncompartmental Pharmacokinetic / Pharmacodynamic Analyses of Clinical Studies” (6) and “Description of Analytical Transfer Files, PK/PD Data files and ADA files” (9).

7.1 DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS

Only descriptive statistics are planned for this section of the report, based on the TS. The data will be summarised by treatment group.

7.2 CONCOMITANT DISEASES AND MEDICATION

Frequency tables are planned for this section of the report, based on the TS.

Concomitant diseases and non-drug therapies will be coded according to the version defined in the decision log (4) of the coding system of the Medical Dictionary for Drug Regulatory Activities (MedDRA). Concomitant medications will be coded according to the most recent version of the World Health Organization Drug Dictionary (WHO-DD). The coding version number will be displayed as a footnote in the respective output.

Section 7.2.5 of the CTP:

Previous and concomitant therapies will be presented per treatment group without consideration of time intervals and treatment periods.

A therapy will be considered concomitant to a treatment, if it

- is ongoing at the time of study drug administration, or
- starts within the analysis phase of the respective treatment (see [Section 6.1](#) for a definition of treatments and analysis phase).

The diagnoses, non-drug therapies and medications will be listed. Subjects without any concomitant diagnoses or concomitant therapies will be marked with a “No” in the respective column.

The relevance of the concomitant therapies to the evaluation of PK will be decided no later than at the RPM.

7.3 TREATMENT COMPLIANCE

Section 4.3 of the CTP:

Compliance will be assured by administration of all trial medication in the trial centre under supervision of the investigating physician or a designee. The measured plasma concentrations and urinary and faecal excretion of trial medication will provide additional confirmation of compliance.

It is not intended to list the compliance separately. Any deviations from complete intake will be addressed in the RPM and described in the CTR.

7.4 PRIMARY OBJECTIVE ANALYSIS

Independent of the main objectives stated in the CTP, this section describes further details of the primary endpoint analyses outlined in the CTP.

7.4.1 Main analysis

Section 7.2.2 of the CTP:

hADME endpoints:

Primary endpoints will be analysed descriptively.

To avoid underestimation of the total recovery of [^{14}C], the excretion during the nonsampling phase of the study will be estimated using linear interpolation between the observed 24-h sampling periods before and after the non-sampling period for urine and faeces, respectively.

Absolute BA endpoints:

The statistical model used for the analysis of dose normalized $\text{AUC}_{0-\infty}$ will be an analysis of variance (ANOVA) model on the logarithmic scale. That is, the PK endpoint will be log-transformed (natural logarithm) prior to fitting the ANOVA model. This model will include effects accounting for the following sources of variation: subject and treatment. The effect 'subject' will be considered as random, whereas the other effect 'treatment' will be considered as fixed. The model is described by the following equation:

$$y_{km} = \mu + s_m + \tau_k + e_{km}, \text{ where}$$

$$y_{km} = \text{logarithm of response measured on subject } m \text{ receiving treatment } k,$$

μ = the overall mean,

s_m = the effect associated with the m^{th} subject, $m = 1, 2, \dots, n$

τ_k = the k^{th} treatment effect, $k = 1, 2$,

e_{km} = the random error associated with the m^{th} subject who received treatment k .

where $s_m \sim N(0, \sigma_B^2)$ i.i.d., $e_{km} \sim N(0, \sigma_W^2)$ i.i.d. and s_m, e_{km} are independent random variables.

Point estimates for the ratios of the geometric means (test/reference) for dose normalized $AUC_{0-\infty}$ [...] and the two-sided 90% confidence intervals (CIs) will be provided.

For dose normalized $AUC_{0-\infty}$, the difference between the expected means for $\log(T)$ - $\log(R)$ will be estimated by the difference in the corresponding adjusted means (Least Squares Means). Additionally, their two-sided 90% CIs will be calculated based on the residual error from the ANOVA and quantiles from the t -distribution. These quantities will then be back-transformed to the original scale to provide the point estimate and 90% CIs.

The implementation for this analysis will be accomplished by using the CSD macros based on the PKS. The following SAS code can be used:

```
PROC MIXED DATA=indata METHOD=REML;  
  CLASS subject treatment;  
  MODEL logpk = treatment / DDFM=KR;  
  RANDOM subject;  
  LSMEANS treatment / PDIF CL ALPHA=0.1;  
RUN;
```

7.5 SECONDARY OBJECTIVE ANALYSIS

Independent of the main objectives stated in the CTP, this section describes further details of the secondary endpoint analyses.


7.5.1 Key secondary objective analysis

This section is not applicable as no key secondary endpoint has been specified in the protocol.

7.5.2 Secondary objective analysis

Section 7.2.3 of the CTP:

The secondary endpoints (refer to CTP Section 2.1.3) will be analysed descriptively.



7.7 EXTENT OF EXPOSURE

Descriptive statistics are planned for this section of the report based on the TS. The date and time of drug administration will be listed for each subject.

7.8 SAFETY ANALYSIS

All safety analyses will be performed on the TS.

The safety data for treated subjects who failed to complete the trial (dropouts or withdrawals) will be reported as far as their data are available. All withdrawals will be documented and the reason for withdrawal recorded.

7.8.1 Adverse Events

AEs will be coded using MedDRA. The coding version number will be displayed as a footnote in the respective output.

Unless otherwise specified, the analyses of AEs will be descriptive in nature. All analyses of AEs will be based on the number of subjects with AEs and NOT on the number of AEs. BI standards as presented in “Analysis and Presentation of Adverse Event Data from Clinical Trials – Display Template” ([11](#)) and “Analysis and Presentation of Adverse Event data from clinical trials” ([12](#)) will be applied.

The analysis of AEs will be based on the concept of treatment emergent AEs. That means that all AEs will be assigned to 'screening', 'on-treatment' or 'follow-up' phases as defined in [Section 6.1](#). AEs will be analysed based on actual treatments, as defined in [Table 6.1: 1](#).

According to the CTP, adverse events of special interest (AESI) will be analysed:

Section 5.2.6.1.4 of the CTP:

The following are considered as AESIs:

- Potential severe DILI

A potential severe Drug Induced Liver Injury (DILI) that requires follow-up is defined by the following alterations of hepatic laboratory parameters:

- *An elevation of AST (aspartate aminotransferase) and/or ALT (alanine aminotransferase) ≥ 3 -fold ULN combined with an elevation of total bilirubin ≥ 2 fold ULN measured in the same blood sample, or in samples drawn within 30 days of each other, OR*
- *An elevation of AST or ALT and INR ≥ 1.5 -fold ULN measured at the same visit, or in samples drawn within 30 days of each other, OR*
- *An elevation of AST or ALT ≥ 3 -fold ULN with new onset, or worsening of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia ($>5\%$), OR*
- *Aminotransferase (ALT, and/or AST) elevations ≥ 5 -fold ULN*

These lab findings constitute a hepatic injury alert and the subjects showing these lab abnormalities need to be followed up according to the 'DILI checklist' provided in the ISF. In case of clinical symptoms of hepatic injury (icterus, unexplained encephalopathy, unexplained coagulopathy, right upper quadrant abdominal pain, etc.) without lab results (ALT, AST, total bilirubin) available, the Investigator should make sure that these parameters are analysed, if necessary in an unscheduled blood test. Should the results meet the criteria of hepatic injury alert, the procedures described in the DILI checklist should be followed.

According to ICH E3 ([13](#)), in addition to deaths and serious AEs, 'other significant' AEs need to be listed in the CTR. These will be any non-serious AE that led to an action taken with study drug (e.g. discontinuation or dose reduced or interrupted).

An overall summary of AEs will be presented.

The frequency of subjects with AEs will be summarised by treatment, primary system organ class (SOC) and preferred term (PT). Separate tables will be provided for subjects with serious AEs, for subjects with drug-related AEs, for subjects with drug-related serious AEs, for subjects with AESIs and for subjects with AEs leading to discontinuation. In addition, the frequency of subjects with AEs will be summarised by worst intensity, treatment, primary SOC and PT.

The system organ classes will be sorted by default alphabetically, PTs will be sorted by frequency (within SOC).

For disclosure of AEs on EudraCT and ClinicalTrials.gov, additional information not included in a standard AE analysis will be performed. The following three entries will be created:

- Adverse Events per arm for disclosure on EudraCT/ClinicalTrials.gov
- Non-serious Adverse Events for disclosure on EudraCT/ClinicalTrials.gov
- Serious Adverse Events for disclosure on EudraCT/ClinicalTrials.gov

Frequencies of subjects with non-serious AEs that had an incidence of > 5% for at least one treatment will be summarised by treatment, primary SOC and PT.

7.8.2 Laboratory data

The analyses of laboratory data will be descriptive in nature and will be based on BI standards as presented in “Handling, Display and Analysis of Laboratory Data” (14). Analyses will be based on normalised values, which means transforming to a standard unit and a standard reference range. The original values will be analysed if the transformation into standard unit is not possible for a parameter.

Laboratory data will be analysed qualitatively via comparison of laboratory data to their reference ranges. Values outside the reference range will be flagged in the data listings.

Clinically relevant findings in laboratory data will be reported as baseline conditions (at screening) or as AEs (during the trial) if judged clinically relevant by the investigator, and will be analysed as such.

It is the investigator's responsibility to decide whether a lab value is clinically significantly abnormal or not (at the RPM at the latest).

Descriptive statistics of haematocrit data including change from baseline will be calculated by planned time point based on the first value of the subject at that planned time point (or assigned to that planned time point). For baseline value, the last measurement before first drug administration will be used.

7.8.3 Vital signs

Descriptive statistics over time including change from baseline will be performed for vital signs (blood pressure and pulse rate). In the listing the change from baseline will also be displayed.


For post-dose measurements of vital signs, descriptive statistics will be calculated by planned time point based on the first value of the subject at that planned time point (or assigned to that planned time point). For baseline value, the last measurement before first drug administration will be used.

Clinically relevant findings will be reported as baseline conditions (at screening) or as AEs (during the trial) if judged clinically relevant by the investigator, and will be analysed as such.

7.8.4 ECG

Clinically relevant abnormal findings will be reported as AEs.

No separate listing or analysis of continuous ECG monitoring will be prepared.




8. TIMEPOINT OF RELEASE OF TREATMENT INFORMATION


The treatment information will be loaded into the trial database during study conduct.

9. REFERENCES

1.	CPMP/ICH/363/96: "Statistical Principles for Clinical Trials", ICH Guideline Topic E9, Note For Guidance on Statistical Principles for Clinical Trials, current version.
----	--



13.	CPMP/ICH/137/95: “Structure and Content of Clinical Study Reports”, ICH Guideline Topic E3; Note For Guidance on Structure and Content of Clinical Study Reports, current version, EMA webpage.



11. HISTORY TABLE

Table 11: 1 History table

Version	Date (DD-MMM-YY)	Author	Sections changed	Brief description of change
1.0	10-DEC-24		None	This is the final TSAP.